StreetInsider.com News Articles

BofA Securities Upgrades Pharvaris B.V. (PHVS) to Buy

Fri, 23 Oct 2026 06:34:39 -0400

(Updated - October 23, 2026 6:34 AM EDT)

BofA Securities analyst Tazeen Ahmad upgraded Pharvaris B.V. (NASDAQ: PHVS) from Neutral to Buy with a price target of $44.00.

The analyst comments "We upgrade Pharvaris (PHVS) to Buy from Neutral and maintain our $44 PO. PHVS is developing deucrictibant (deucri), a pill to both treat (on-demand) and prevent (prophy) attacks of hereditary angioedema (HAE), a rare genetic disease that causes sudden and sometimes life-threatening swelling attacks. This would make PHVS the only company with oral options in both settings. Shares have pulled back since the positive ph 3 prophy data in September, which

BofA Securities Upgrades Pharvaris B.V. (PHVS) to Buy

Fri, 23 Oct 2026 06:34:39 -0400

(Updated - October 23, 2026 6:34 AM EDT)

BofA Securities analyst Tazeen Ahmad upgraded Pharvaris B.V. (NASDAQ: PHVS) from Neutral to Buy with a price target of $44.00.

Form 4 Pharvaris N.V. For: Oct 11 Filed by: Lu Peng

Tue, 13 Oct 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20261013/27181216.html

Pharvaris publishes phase 3 deucrictibant HAE study results in The Lancet

Thu, 08 Oct 2026 18:35:16 -0400

Pharvaris (Nasdaq: PHVS) announced that results from its RAPIDe-3 phase 3 study evaluating oral deucrictibant immediate-release (IR) capsules for the on-demand treatment of hereditary angioedema (HAE) attacks have been published in The Lancet.

The global, randomized, double-blind, placebo-controlled crossover study met its primary endpoint and all 11 secondary endpoints. Deucrictibant IR showed a median time to onset of symptom relief of 1.28 hours and a median time to complete symptom resolution of 11.95 hours. Most attacks were controlled with a single capsule, and the treatment was reported as well tolerated with no safety signals observed.

Results were consistent across subgroups defined by

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Thu, 08 Oct 2026 18:35:00 -0400

Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)
Deucrictibant IR showed a well-tolerated safety profile
NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Thu, 08 Oct 2026 18:35:00 -0400

Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)
Deucrictibant IR showed a well-tolerated safety profile
NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities

H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)

Tue, 06 Oct 2026 06:56:22 -0400

H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $60.00 price target on Pharvaris B.V. (NASDAQ: PHVS).

The analyst commented: "We recently hosted Pharvaris management at our 28th Annual Global Investment Conference and have since conducted a deep-dive analysis of the upcoming catalysts for deucrictibant, an oral bradykinin B2 receptor antagonist that has produced positive Phase 3 data in both on-demand treatment (RAPIDe-3) and prophylaxis (CHAPTER-3) of hereditary angioedema (HAE) attacks. In CHAPTER-3, once-daily extended-release (XR) deucrictibant reduced the mean monthly attack rate by 83% versus placebo across all three HAE types; an additional analysis not adjusted for multiplicity

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Mon, 05 Oct 2026 06:50:00 -0400

Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options

ZUG, Switzerland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS) a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that insights from a Pharvaris-funded analysis of the multinational Adelphi Real World HAE Disease Specific Programme™ (DSP) dataset evaluating how HAE is

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Mon, 05 Oct 2026 06:50:00 -0400

Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options

Form 4 Pharvaris N.V. For: Sep 23 Filed by: Monges Viviane

Fri, 25 Sep 2026 13:36:00 -0400

si-local-file:///var/storage/secattach/20260925/27106388.html

Form 4 Pharvaris N.V. For: Sep 22 Filed by: Lu Peng

Thu, 24 Sep 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260924/27102154.html

Form 4 Pharvaris N.V. For: Sep 22 Filed by: Schikan Johannes Gerardus Christiaan Petrus

Thu, 24 Sep 2026 10:43:00 -0400

si-local-file:///var/storage/secattach/20260924/27100441.html

Form 144 Pharvaris N.V. Filed by: Monges Viviane

Wed, 23 Sep 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260923/27096981.html

Form 4 Pharvaris N.V. For: Sep 21 Filed by: Nassif David W.

Wed, 23 Sep 2026 10:06:00 -0400

si-local-file:///var/storage/secattach/20260923/27094680.html

Form 144/A Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus

Tue, 22 Sep 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260922/27091304.html

Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus

Tue, 22 Sep 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260922/27091202.html

Form 4 Pharvaris N.V. For: Sep 17 Filed by: Lu Peng

Mon, 21 Sep 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260921/27085578.html

Form 4 Pharvaris N.V. For: Sep 17 Filed by: Schikan Johannes Gerardus Christiaan Petrus

Mon, 21 Sep 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260921/27085555.html

Form 144 Pharvaris N.V. Filed by: Nassif David W.

Mon, 21 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260921/27085386.html

Form 4 Pharvaris N.V. For: Sep 17 Filed by: Bjork Elisabeth

Mon, 21 Sep 2026 15:21:00 -0400

si-local-file:///var/storage/secattach/20260921/27085158.html

Form 4 Pharvaris N.V. For: Sep 17 Filed by: Glassman Robert

Mon, 21 Sep 2026 15:17:00 -0400

si-local-file:///var/storage/secattach/20260921/27085145.html

Form 4 Pharvaris N.V. For: Sep 17 Filed by: Lesage Anne

Mon, 21 Sep 2026 15:14:00 -0400

si-local-file:///var/storage/secattach/20260921/27085136.html

Form 4 Pharvaris N.V. For: Sep 17 Filed by: Modig Berndt

Mon, 21 Sep 2026 15:11:00 -0400

si-local-file:///var/storage/secattach/20260921/27085129.html

Form 144 Pharvaris N.V. Filed by: Lu Peng

Thu, 17 Sep 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260917/27077138.html

Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus

Thu, 17 Sep 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260917/27076889.html